medigraphic.com
Revista Médica Sinergia

2020, Number 01

<< Back Next >>

Revista Médica Sinergia 2020; 5 (01)

Vogt-Koyanagi-Harada disease

Pabón PCA, Noboa JAM, Orias DJM

Language: Spanish
References: 16
Page: 338
PDF size: 166.58 Kb.


ABSTRACT

Vogt-Koyanagi-Harada Syndrome refers to an idiopathic, multisystemic and autoimmune disease, which compromises organs rich in melanocytes, mainly eyes, generating recurrent cases of uveitis associated with auditory, neurological and skin symptoms. This disorder involves innate, humoral and cellular immunity, with antigenic targets of the tyrosinase family and gp100 in people with a genetic predisposition to melanocyte intolerance through specific HLA expression. Most patients with the syndrome debut with an episode similar to a viral condition, which subsequently associates uveitic symptoms, which, if not treated in time, lead to recurrence and chronicity of the disease that can lead to blindness and hearing impairment, because of this, professionals must make a successful early diagnosis. Currently, the management of this disease is based on the early establishment of a triple therapy with systemic corticosteroids, non-steroidal immunosuppressants and biological response modifiers; these last ones are being studied in order to provide new complementary therapeutic options.


REFERENCES

  1. Lavezzo MM, Sakata VM, Morita C, Rodriguez EEC, Abdallah SF, da Silva FTG, Hirata CE, Yamamoto JH. Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet Journal of Rare Diseases. 2016 03 24;11(1). https://doi.org/10.1186/s13023-016- 0412-4

  2. Guayacán CL, Galindo-Mendez B, de-la-Torre A. Vogt–Koyanagi–Harada Syndrome in a Group of Patients in Two Ophthalmology Referral Centers in Bogotá, Colombia. Ocular Immunology and Inflammation. 2017 09 14;26(7):1123-1127. https://doi.org/10.1080/09273948.2017.1341536

  3. Chiquito Freile MC, Gutiérrez Mendoza JP. Síndrome de Vogt-Koyanagi-Harada: presentación de un caso clínico.. Medicina. 2015 Nov 18;19(1):45. https://doi.org/10.23878/medicina.v19i1.644

  4. Zúñiga J, Rodas O, Morales I, Madrid B, Lagos L. Síndrome de Vogt-Koyanagi-Harada a propósito de un caso. Archivos de Medicina. 2016; 12(1): 1-4. https://doi.org/10.3823/1277

  5. Hedayatfar A, Khochtali S, Khairallah M, Takeuchi M, El Asrar AA, Herbort CP. “Revised diagnostic criteria” for Vogt-Koyanagi-Harada disease fail to improve disease management. Journal of Current Ophthalmology. 2019 03;31(1):1-7. https://doi.org/10.1016/j.joco.2018.10.011

  6. O'Keefe GAD, Rao NA. Vogt-Koyanagi-Harada disease. Survey of Ophthalmology. 2017 01;62(1):1- 25. https://doi.org/10.1016/j.survophthal.2016.05.002

  7. Betancourt R, Betancourt SA, Soler G, Mantilla RD, Castillo GA. Enfermedad de Vogt Koyanagi Harada. Reporte de un caso y revisión de la literatura. Revista Colombiana de Reumatología. 2019 05;. https://doi.org/10.1016/j.rcreu.2018.12.002

  8. Herbort CP, Abu El Asrar AM, Takeuchi M, Pavésio CE, Couto C, Hedayatfar A, Maruyama K, Rao X, Silpa-archa S, Somkijrungroj T. Catching the therapeutic window of opportunity in early initial-onset Vogt– Koyanagi–Harada uveitis can cure the disease. International Ophthalmology. 2018 06 11;39(6):1419- 1425. https://doi.org/10.1007/s10792-018-0949-4

  9. Sakata VM, da Silva FT, Hirata CE, de Carvalho JF, Yamamoto JH. Diagnosis and classification of Vogt– Koyanagi–Harada disease. Autoimmunity Reviews. 2014 04;13(4-5):550- 555. https://doi.org/10.1016/j.autrev.2014.01.023

  10. Abu El-Asrar AM, Dosari M, Hemachandran S, Gikandi PW, Al-Muammar A. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus’ in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmologica. 2016 08 18;95(1):85-90. https://doi.org/10.1111/aos.13189

  11. Benavente A, Perez S, El-Ahmed H, Alfara A. Vogt-Koyanagi-Harada Disease, a Rare Entity in Spain: The Challenge of Worldwide Immigration and Globalization. European Journal of Case Reports in Internal Medicine. 2018; 5(7). https://doi.org/10.12890/2018_000886

  12. Ng JY, Luk FO, Lai TY, Pang C. Influence of molecular genetics in Vogt-Koyanagi-Harada disease. Journal of Ophthalmic Inflammation and Infection. 2014 07 22;4(1). https://doi.org/10.1186/s12348-014-0020-1

  13. Quintero Busutil Mayrelis, Vilches Lescalle Daysi Caridad, Bueno Arrieta Yurania, Rodríguez Masó Susana, Perea Ruíz Carlos Alberto, Paz Lorenzo Miladis. Enfermedad de Vogt-Koyanagi-Harada y rehabilitación visual. Rev Cubana Oftalmol [Internet]. 2015 Mar [citado 2019 Dic 21] ; 28( 1 ). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762015000100016&lng=es.

  14. Sheriff F, Narayanan NS, Huttner AJ, Baehring JM. Vogt-Koyanagi-Harada syndrome: A novel case and brief review of focal neurologic presentations. Neurology - Neuroimmunology Neuroinflammation. 2014 Nov 20;1(4):e49. https://doi.org/10.1212/nxi.0000000000000049

  15. Rosenbaum J. Uveitis: Etiology, clinical manifestations, and diagnosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. 2018. Disponible en: https://www.uptodate.com/contents/uveitis-etiology-clinicalmanifestations- and-diagnosis

  16. Liu C, Francis J, Pulido J, Abramson D. Ocular side effects of systemically administered chemotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. 2019. Disponible en: https://www.uptodate.com/contents/ocular-side-effects-of-systemically-administeredchemotherapy? search=Ocular%20side%20effects%20of%20systemically%20administered%20chemother




2020     |     www.medigraphic.com